ADVERTISEMENT
Abstracts
P037
Polatuzumab Vedotin Combined with Immunochemotherapy in Relapsed/Refractory Patients with Diffuse Large B-cell Lymphoma: A Retrospective, Real Life Study of KROHEM(Croatian Cooperative Group for Hematologic Disease)
Introduction:
Despite therapeutic advances, patients with relapsed or refractory (R/R) DLBCL have a dire prognosis. Polatuzumab-vedotin (PoV), an antibody-drug conjugate (ADC) targeting anti CD 79b and containing the antimitotic MMAE is active in combination with immunochemotherapy in this setting.The aim of this paper is to report outcomes of patients with R/R DLBCL treated with PoV in a real-life setting
Methods:
Patients from 9 hematology centers in Croatia received PoV through a compassionate-use program sponsored by Roche. Data on efficacy and toxicity were collected retrospectively by chart review. PoV was administered at a dose of 1.8 mg/kg/cycle iv in combination with an anti-CD20 monoclonal antibody and chemotherapy for a total of up to 6 cycles. Response was assessed after 3 cycles and at end of treatment.
Results:
48 adult patients (27 males, 21 females) with median age of 69 y (range 32-89) were treated from July 2017 until February 2022. 30 (64%) patients were refractory or in early relapse after first line therapy. Median number of prior treatment lines was 3 (range 1-5).
Discussion:
PoV in combination with immunochemotherapy produced promising results in this group of unselected, high-risk, real-life patients with predominantly refractory or early relapsing DLBCL. Beneficial effects of treatment with little toxicity seem limited to fit patients
Despite therapeutic advances, patients with relapsed or refractory (R/R) DLBCL have a dire prognosis. Polatuzumab-vedotin (PoV), an antibody-drug conjugate (ADC) targeting anti CD 79b and containing the antimitotic MMAE is active in combination with immunochemotherapy in this setting.The aim of this paper is to report outcomes of patients with R/R DLBCL treated with PoV in a real-life setting
Methods:
Patients from 9 hematology centers in Croatia received PoV through a compassionate-use program sponsored by Roche. Data on efficacy and toxicity were collected retrospectively by chart review. PoV was administered at a dose of 1.8 mg/kg/cycle iv in combination with an anti-CD20 monoclonal antibody and chemotherapy for a total of up to 6 cycles. Response was assessed after 3 cycles and at end of treatment.
Results:
48 adult patients (27 males, 21 females) with median age of 69 y (range 32-89) were treated from July 2017 until February 2022. 30 (64%) patients were refractory or in early relapse after first line therapy. Median number of prior treatment lines was 3 (range 1-5).
Discussion:
PoV in combination with immunochemotherapy produced promising results in this group of unselected, high-risk, real-life patients with predominantly refractory or early relapsing DLBCL. Beneficial effects of treatment with little toxicity seem limited to fit patients
Publisher
John Wiley & Sons; Hoboken, USA
Source Journal
American Journal of Hematology
2022 Wiley Periodicals LLC.
